Submitted:
30 December 2022
Posted:
03 January 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
2.1. Characteristics of Pulmonary hypertension:
2.2. Proteomic analysis of PVB vs control in the upper and lower lobe:
2.3. Metabolomic profiling of the lower and upper lobe versus control
2.5. Network analysis of proteomics and metabolomics datasets
2.6. Protein and transcriptional regulation of fatty acids uptake in upper lobe
3. Discussion
4. Materials and Methods
4.1. Outline of Study
4.2. Real time quantitative PCR of lung tissue
4.3. Proteomics
4.3.1. Sample preparation for proteome analysis
4.3.2. Nano-liquid chromatography (LC)–tandem mass spectrometry (MS) analysis and bioinformatics
4.4. Metabolomics:
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
References
- S. Rosenkranz, J. S. R. Gibbs, R. Wachter, T. de Marco, A. Vonk-Noordegraaf, and J.-L. Vachiéry, ‘Left ventricular heart failure and pulmonary hypertension’, Eur Heart J, vol. 37, no. 12, pp. 942–954, Mar. 2016. [CrossRef]
- N. Galiè et al., ‘2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension’, Eur Heart J, vol. 37, no. 1, pp. 67–119, Jan. 2016. [CrossRef]
- C. H. Backes et al., ‘Pulmonary Vein Stenosis in Infants: A Systematic Review, Meta-Analysis, and Meta-Regression’, J Pediatr, vol. 198, pp. 36-45.e3, Jul. 2018. [CrossRef]
- S. Gowda, D. Bhat, Z. Feng, C.-H. Chang, and R. D. Ross, ‘Pulmonary Vein Stenosis with Down Syndrome: A Rare and Frequently Fatal Cause of Pulmonary Hypertension in Infants and Children’, Congenit Heart Dis, vol. 9, no. 3, pp. E90–E97, May 2014. [CrossRef]
- C. Riccardo, ‘Pulmonary Vein Stenosis Following Radiofrequency Ablation of Atrial Fibrillation’, JACC Clin Electrophysiol, vol. 3, no. 6, pp. 599–601, Jun. 2017. [CrossRef]
- L. Mahgoub et al., ‘Pulmonary vein stenosis of ex-premature infants with pulmonary hypertension and bronchopulmonary dysplasia, epidemiology, and survival from a multicenter cohort’, Pediatr Pulmonol, vol. 52, no. 8, pp. 1063–1070, Aug. 2017. [CrossRef]
- R. W. B. van Duin et al., ‘Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: a key role for endothelin’, Journal of Physiology, vol. 597, no. 4, pp. 1157–1173, 2019. [CrossRef]
- D. Wu and K. Birukov, ‘Endothelial Cell Mechano-Metabolomic Coupling to Disease States in the Lung Microvasculature’, Front Bioeng Biotechnol, vol. 7, Jul. 2019. [CrossRef]
- S. Tyanova, T. Temu, and J. Cox, ‘The MaxQuant computational platform for mass spectrometry-based shotgun proteomics.’, Nat Protoc, vol. 11, no. 12, pp. 2301–2319, Dec. 2016. [CrossRef]
- ‘R Core Team (2021) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna. https://www.R-project.orgNo Title’.
- C. Ammar, M. Gruber, G. Csaba, and R. Zimmer, ‘MS-EmpiRe Utilizes Peptide-level Noise Distributions for Ultra-sensitive Detection of Differentially Expressed Proteins.’, Mol Cell Proteomics, vol. 18, no. 9, pp. 1880–1892, Sep. 2019. [CrossRef]
- F. Flenkenthaler et al., ‘Differential Effects of Insulin-Deficient Diabetes Mellitus on Visceral vs. Subcutaneous Adipose Tissue-Multi-omics Insights From the Munich MIDY Pig Model.’, Front Med (Lausanne), vol. 8, p. 751277, 2021. [CrossRef]
- D. Szklarczyk et al., ‘STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.’, Nucleic Acids Res, vol. 47, no. D1, pp. D607–D613, Jan. 2019. [CrossRef]
- F. Supek, M. Bošnjak, N. Škunca, and T. Šmuc, ‘REVIGO summarizes and visualizes long lists of gene ontology terms.’, PLoS One, vol. 6, no. 7, p. e21800, 2011. [CrossRef]
- D. Kessner, M. Chambers, R. Burke, D. Agus, and P. Mallick, ‘ProteoWizard: Open source software for rapid proteomics tools development’, Bioinformatics, vol. 24, no. 21, pp. 2534–2536, Nov. 2008. [CrossRef]
- C. A. Smith, E. J. Want, G. O’Maille, R. Abagyan, and G. Siuzdak, ‘XCMS: Processing Mass Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and Identification’, Anal Chem, vol. 78, no. 3, pp. 779–787, Feb. 2006. [CrossRef]
- D. S. Wishart et al., ‘HMDB 4.0: the human metabolome database for 2018’, Nucleic Acids Res, vol. 46, no. D1, pp. D608–D617, Jan. 2018. [CrossRef]
- H. Tsugawa et al., ‘MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis’, Nat Methods, vol. 12, no. 6, pp. 523–526, Jun. 2015. [CrossRef]
- Y. Perez-Riverol et al., ‘The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences.’, Nucleic Acids Res, vol. 50, no. D1, pp. D543–D552, Jan. 2022. [CrossRef]
- R. W. B. van Duin et al., ‘Intervening with the nitric oxide pathway to alleviate pulmonary hypertension in pulmonary vein stenosis’, J Clin Med, vol. 8, no. 8, Aug. 2019. [CrossRef]
- Rafikova, I. al Ghouleh, and R. Rafikov, ‘Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development’, Antioxid Redox Signal, vol. 31, no. 13, pp. 933–953, Jun. 2019. [CrossRef]
- N. Villalba, S. Baby, and S. Y. Yuan, ‘The Endothelial Glycocalyx as a Double-Edged Sword in Microvascular Homeostasis and Pathogenesis’, Front Cell Dev Biol, vol. 9, Jul. 2021. [CrossRef]
- T. Thenappan, S. Y. Chan, and E. K. Weir, ‘Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension’, American Journal of Physiology-Heart and Circulatory Physiology, vol. 315, no. 5, pp. H1322–H1331, Nov. 2018. [CrossRef]
- P. Chelladurai, W. Seeger, and S. S. Pullamsetti, ‘Matrix metalloproteinases and their inhibitors in pulmonary hypertension’, European Respiratory Journal, vol. 40, no. 3, p. 766, Sep. 2012. [CrossRef]
- C. R. White, G. Datta, L. Wilson, M. N. Palgunachari, and G. M. Anantharamaiah, ‘The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage’, Chem Phys Lipids, vol. 219, pp. 28–35, Mar. 2019. [CrossRef]
- S. Sharma et al., ‘Apolipoprotein A-I mimetic peptide 4f rescues pulmonary hypertension by inducing MicroRNA-193-3p’, Circulation, vol. 130, no. 9, pp. 776–785, 2014. [CrossRef]
- C. de Carvalho and M. Caramujo, ‘The Various Roles of Fatty Acids’, Molecules, vol. 23, no. 10, p. 2583, Oct. 2018. [CrossRef]
- C. E. Storniolo, J. Roselló-Catafau, X. Pintó, M. T. Mitjavila, and J. J. Moreno, ‘Polyphenol fraction of extra virgin olive oil protects against endothelial dysfunction induced by high glucose and free fatty acids through modulation of nitric oxide and endothelin-1’, Redox Biol, vol. 2, no. 1, pp. 971–977, 2014. [CrossRef]
- X. Du, D. Edelstein, S. Obici, N. Higham, , Ming-Hui Zou, and M. Brownlee, ‘Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation’, Journal of Clinical Investigation, vol. 116, no. 4, pp. 1071–1080, Apr. 2006. [CrossRef]
- Ghosh, L. Gao, A. Thakur, P. M. Siu, and C. W. K. Lai, ‘Role of free fatty acids in endothelial dysfunction’, J Biomed Sci, vol. 24, no. 1, p. 50, Dec. 2017. [CrossRef]
- D. Huang et al., ‘HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression’, Cell Rep, vol. 8, no. 6, pp. 1930–1942, Sep. 2014. [CrossRef]
- W. Xu, A. J. Janocha, and S. C. Erzurum, ‘Metabolism in Pulmonary Hypertension’, Annual Review of Physiology, vol. 83. Annual Reviews Inc., pp. 551–576, Feb. 10, 2021. [CrossRef]
- S. Umar et al., ‘Involvement of Low-Density Lipoprotein Receptor in the Pathogenesis of Pulmonary Hypertension’, J Am Heart Assoc, vol. 9, no. 2, Jan. 2020. [CrossRef]
- J. L. Goldstein and M. S. Brown, ‘The LDL Receptor’, Arterioscler Thromb Vasc Biol, vol. 29, no. 4, pp. 431–438, Apr. 2009. [CrossRef]
- M. Kockx, M. Traini, and L. Kritharides, ‘Cell-specific production, secretion, and function of apolipoprotein E’, J Mol Med, vol. 96, no. 5, pp. 361–371, May 2018. [CrossRef]
- Y. Zhang, K. L. Ma, X. Z. Ruan, and B. C. Liu, ‘Dysregulation of the low-density lipoprotein receptor pathway is involved in lipid disorder-mediated organ injury’, Int J Biol Sci, vol. 12, no. 5, pp. 569–579, 2016. [CrossRef]
- G. Venturini et al., ‘Integrated proteomics and metabolomics analysis reveals differential lipid metabolism in human umbilical vein endothelial cells under high and low shear stress’, American Journal of Physiology-Cell Physiology, vol. 317, no. 2, pp. C326–C338, Aug. 2019. [CrossRef]
- J. L. Izquierdo-Garcia et al., ‘Metabolic Reprogramming in the Heart and Lung in a Murine Model of Pulmonary Arterial Hypertension’, Front Cardiovasc Med, vol. 5, Aug. 2018. [CrossRef]
- P. Vaupel and G. Multhoff, ‘Revisiting the Warburg effect: historical dogma versus current understanding’, Journal of Physiology, vol. 599, no. 6. John Wiley and Sons Inc, pp. 1745–1757, Mar. 01, 2021. [CrossRef]
- L. Agledal, M. Niere, and M. Ziegler, ‘The phosphate makes a difference: cellular functions of NADP’, Redox Report, vol. 15, no. 1, pp. 2–10, Feb. 2010. [CrossRef]
- S. B. Nukala et al., ‘Protein network analyses of pulmonary endothelial cells in chronic thromboembolic pulmonary hypertension’, Sci Rep, vol. 11, no. 1, Dec. 2021. [CrossRef]
- L. Sibal, S. C Agarwal, P. D Home, and R. H Boger, ‘The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease’, Curr Cardiol Rev, vol. 6, no. 2, pp. 82–90, May 2010. [CrossRef]
- N. Skoro-Sajer et al., ‘Asymmetric Dimethylarginine Is Increased in Chronic Thromboembolic Pulmonary Hypertension’, Am J Respir Crit Care Med, vol. 176, no. 11, pp. 1154–1160, Dec. 2007. [CrossRef]
- W. Murray, ‘The Biological Significance of Purine Salvage’, Annu Rev Biochem, vol. 40, no. 1, pp. 811–826, Jun. 1971. [CrossRef]
- T. Hautbergue et al., ‘Right ventricle remodeling metabolic signature in experimental pulmonary hypertension models of chronic hypoxia and monocrotaline exposure’, Cells, vol. 10, no. 6, Jun. 2021. [CrossRef]
- W. Xu et al., ‘Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension’, Sci Rep, vol. 9, no. 1, Dec. 2019. [CrossRef]
- M. A. GIMBRONE, J. N. TOPPER, T. NAGEL, K. R. ANDERSON, and G. GARCIA-CARDEÑA, ‘Endothelial Dysfunction, Hemodynamic Forces, and Atherogenesisa’, Ann N Y Acad Sci, vol. 902, no. 1, pp. 230–240, Jan. 2006. [CrossRef]








Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).